imiquimod has been researched along with Bright Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Asanuma, K; Fukuta, M; Iida, K; Iwamoto, T; Iwata, A; Kojima, S; Maezawa, Y; Makino, S; Nakagomi, D; Nakajima, H; Suto, A; Suzuki, K; Takemoto, M; Tanaka, S; Wakashin, H; Yabe, Y; Yamada, H | 1 |
| Anders, HJ; Kretzler, M; Patole, PS; Pawar, RD; Schlöndorff, D; Segerer, S; Zecher, D | 1 |
| Anders, HJ; Kulkarni, OP; Lech, M; Lichtnekert, J; Patole, PS; Pawar, RD; Ramanjaneyulu, A; Segerer, S | 1 |
3 other study(ies) available for imiquimod and Bright Disease
| Article | Year |
|---|---|
Suppressor of cytokine signalling 3 (SOCS3) expressed in podocytes attenuates glomerulonephritis and suppresses autoantibody production in an imiquimod-induced lupus model.
Topics: Animals; Cytokines; Glomerulonephritis; Imiquimod; Mice; Mice, Inbred BALB C; Podocytes; Suppressor of Cytokine Signaling 3 Protein | 2021 |
Toll-like receptor-7 modulates immune complex glomerulonephritis.
Topics: Aminoquinolines; Animals; Antibody Formation; Antigen-Antibody Complex; Cells, Cultured; Chemokine CCL2; Female; Glomerulonephritis; Imiquimod; Immune Complex Diseases; Inflammation Mediators; Interleukin-12; Interleukin-6; Lupus Nephritis; Macrophages; Membrane Glycoproteins; Mice; Mice, Inbred MRL lpr; RNA, Messenger; Toll-Like Receptor 7 | 2006 |
Coactivation of Toll-like receptor-3 and -7 in immune complex glomerulonephritis.
Topics: Aminoquinolines; Animals; Antibodies, Antinuclear; Autoantibodies; Dendritic Cells; Female; Glomerulonephritis; Imiquimod; Immune Complex Diseases; Immunoglobulin G; Interferon-gamma; Interleukin-12; Interleukin-6; Mice; Mice, Inbred MRL lpr; RNA; Toll-Like Receptor 4; Toll-Like Receptor 7; Tumor Necrosis Factors | 2007 |